tbuckley/cabot-search huggingface dataset:
P1.16-31 Body Mass Index Relating to Patient-Reported Symptoms in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Authors: Q. Shi, L. Williams, B. El Ferjani, M. Hirschmann, D. Ponce, S. Dibaj, S. Chandwani, E. Roarty, W. Rinsurongkawong, J. Lewis, T. Burke, C. Cleeland, J. Lee, J. Roth, S. Swisher, J. Heymach, J. Zhang, G. Simon
Journal: Journal of Thoracic Oncology (2019)
Effect of Continuous Lenalidomide Treatment on Copy Number Alteration and Cytogenetic Abnormalities in Multiple Myeloma Cells
Authors: Paola Storti, Marina Bolzoni, Francesca Novara, Giannalisa Todaro, Valentina Marchica, Federica Costa, Tania Maldacena, Laura Notarfranchi, Fabrizio Accardi, Orsetta Zuffardi, Franco Aversa, Nicola Giuliani, Gabriella Sammarelli
Journal: Blood (2017)
Identification of Anonymous MRI Research Participants with Face-Recognition Software
Authors: Christopher G Schwarz, Walter K Kremers, Terry M Therneau, Richard R Sharp, Jeffrey L Gunter, Prashanthi Vemuri, Arvin Arani, Anthony J Spychalla, Kejal Kantarci, David S Knopman, Ronald C Petersen, Clifford R Jack
Journal: New England Journal of Medicine (2019)

Facial Identification from Cranial MRI With the use of publicly available software, reconstructed facial images from deidentified cranial MRI scans were matched to photographs of individual study p...
EP1.18-08 Pulmonary Lobectomy and Completion Pneumonectomy for Ipsilateral Lung Cancer After Radical Resection
Authors: M. Okazaki, K. Suzawa, K. Miyoshi, S. Otani, H. Yamamoto, S. Sugimoto, M. Yamane, T. Oto, S. Toyooka
Journal: Journal of Thoracic Oncology (2019)
P1.01-135 Salvage Chemotherapy After Immunotherapy Failure in Non-Small-Cell Lung Cancer Patients
Authors: G. Randon, G. Galli, A. De Toma, F. Pagani, B. Trevisan, D. Signorelli, C. Proto, A. Prelaj, R. Ferrara, M. Ganzinelli, L. Pallavicini, R. Di Mauro, N. Zilembo, F. De Braud, M. Garassino, G. Lo Russo
Journal: Journal of Thoracic Oncology (2019)
Psychiatric and Psychosomatic Consultation-Liaison Services in General Hospitals: A Systematic Review and Meta-Analysis of Effects on Symptoms of Depression and Anxiety
Authors: Barbara Stein, Markus M. Müller, Lisa K. Meyer, Wolfgang Söllner
Journal: Psychotherapy and Psychosomatics (2019)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Psychiatric and psychosomatic consultation-liaison services (CL) are important providers of diagnosis and treatment for hospital patients with mental comorbidities and psychological burdens. &lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; To perform a systematic review and meta-analysis investigating the effects of CL on depression and anxiety. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Following PRISMA guidelines, a systematic literature search was conducted until 2017. Included were published randomized controlled trials using CL interventions with adults in general hospitals, treatment as usual as control groups, and depression and/or anxiety as outcomes. Risk of bias was assessed using the Cochrane Risk of Bias Tool. Level of integration was assessed using the Standard Framework for Levels of Integrated Healthcare. Meta-analyses were performed using random effects models and meta-regression for moderator effects. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; We included 38 studies (9,994 patients). Risk of bias was high in 17, unclear in 15, and low in 6 studies. Studies were grouped by type of intervention: brief interventions tailored to the patients (8), interventions based on specific treatment manuals (19), and integrated, collaborative care (11). Studies showed small to medium effects on depression and anxiety. Meta-analyses for depression yielded a small effect (&lt;i&gt;d&lt;/i&gt; = –0.19, 95% CI: –0.30 to –0.09) in manual studies and a small effect (&lt;i&gt;d&lt;/i&gt; = –0.33, 95% CI: –0.53 to –0.13) in integrated, collaborative care studies, the latter using mostly active control groups with the possibility of traditional consultation. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; CL can provide a helpful first treatment for symptoms of depression and anxiety. Given that especially depressive symptoms in medically ill patients are long-lasting, the results underline the benefit of integrative approaches that respect the complexity of the illness.
EP1.11-12 Lung Cancer Screening: Implementation in a Multi-State, Community-Based Setting
Authors: C. Wilshire, S. Anton, C. Henson, L. Horslen, C. Fuller, B. Mccall, K. Spiegel, J. Rayburn, A. Carlson, C. Gilbert, J. Gorden
Journal: Journal of Thoracic Oncology (2019)
Phenomapping of patients with heart failure with preserved ejection fraction using machine learning‐based unsupervised cluster analysis
Authors: Matthew W. Segar, Kershaw V. Patel, Colby Ayers, Mujeeb Basit, W.H. Wilson Tang, Duwayne Willett, Jarett Berry, Justin L. Grodin, Ambarish Pandey
Journal: European Journal of Heart Failure (2019)
Recombinant Human Coagulation Factor IX Expressed in HEK293 Cells: Influence of Serin Phosphorylation and Tyrosine Sulfation on Pharmacokinetic Properties in FIX-Knock-out Mice
Authors: Ernst Boehm, Michael Dockal, Meinhard Hasslacher, Artur Mitterer, Eva M Muchitsch, Manfred Reiter, Friedrich Scheiflinger
Journal: Blood (2008)
OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
Authors: F. Barlesi, C. Audigier-Valette, E. Felip, T. Ciuleanu, K. Jao, E. Rijavec, L. Urban, J. Aucoin, C. Zannori, K. Vermaelen, O.A. Frontera, N. Ready, A. Curioni Fontecedro, H. Linardou, E. Poddubskaya, J. Fischer, I. Iordan, H. Groen, R. Pillai, S. Li, J. Fiore, H. Chang, A. Acevedo, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2019)
Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies
Authors: Kazuya Kariyama, Kazuhiro Nouso, Akiko Wakuta, Ayano Oonishi, Hidenori Toyoda, Toshifumi Tada, Atsushi Hiraoka, Kunihiko Tsuji, Ei Itobayashi, Toru Ishikawa, Koichi Takaguchi, Akemi Tsutsui, Noritomo Shimada, Takashi Kumada
Journal: Liver Cancer (2019)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Transcatheter arterial chemoembolization (TACE) is the standard therapy for intermediate-stage (IM) hepatocellular carcinoma (HCC). However, IM-HCC includes various clinical conditions, and various therapies were conducted in practice. In this study, we retrospectively analyzed the actually conducted treatments for IM-HCC and their efficacies to elucidate the treatment strategies suitable for IM-HCC. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; This study included 627 IM-HCC of 5,260 HCC from 9 hospitals. We examined the treatment strategies of these patients and analyzed the efficacy of each therapy with the Cox proportional hazard model and propensity score-matched analysis. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Liver resection, radiofrequency ablation (RFA), and TACE were performed in 165, 108, and 351 patients, respectively. Liver resection and RFA were preferably selected in cases of Barcelona Clinic Liver Cancer (BCLC)-B1/B2, and patient survival was significantly longer than in those treated with TACE (&lt;i&gt;p&lt;/i&gt;&amp;#x3c; 0.0001). However, no beneficial effect of these active therapies was observed in cases of BCLC-B3/B4. Multivariate analysis revealed that surgical resection (hazard ratio = 0.384) and RFA (hazard ratio = 0.597) were negative risk factors for survival. Propensity score-matching analysis revealed that ­survival of RFA-treated patients was longer than that of TACE-treated patients (&lt;i&gt;p&lt;/i&gt; = 0.036). &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; RFA and surgical resection were effective for IM-HCC, particularly in BCLC-B1/B2 cases.
P2.17-20 A Radiomic Approach to Predict Nodal and Distant Relapse in Patients Treated with Stereotactic Body Radiation Therapy for Early Stage NSCLC
Authors: D. Franceschini, L. Cozzi, D. Pezzulla, F. De Rose, C. Franzese, S. Tomatis, M. Scorsetti
Journal: Journal of Thoracic Oncology (2019)
P1.17-39 Preoperative Prediction of Incomplete Resection in Non-Small Cell Lung Cancer: An Externally Validated Clinical Nomogram
Authors: M. Rasing, M. Peters, A. Moreno, E. Hofman, J. Herder, P. Welvaart, F. Schramel, J. Lodeweges, S. Lin, J. Verhoeff, P. Van Rossum
Journal: Journal of Thoracic Oncology (2019)
P2.01-09 VinMetAtezo: Phase II Trial of Metronomic Oral Vinorelbine with Atezolizumab for Recurrent Stage IV NSCLC (GFPC*04-08)
Authors: A. Vergnenegre, G. Robinet, C. Chouaid, A. Bizieux, I. Monnet, C. Ricordel
Journal: Journal of Thoracic Oncology (2019)
Government’s pension proposals won’t stop doctors reducing hours, says BMA
Authors: Zosia Kmietowicz
Journal: BMJ (2019)

The BMA has called the government’s plans to make the NHS pension scheme more workable for senior doctors a “sticking plaster” that will not stop doctors cutting back their hours or prevent them from retiring early.

In August the government set out plans to widen the options available in the NHS pension scheme,1 to encourage the most highly paid doctors in England and Wales not to reduce their hours for tax reasons.

Current pension and tax rules, introduced in 2016, can lead doctors to avoid taking on extra work for fear of being hit by substantial tax charges.

The new …
Trends and Focus of Machine Learning Applications for Health Research
Authors: Brett Beaulieu-Jones, Samuel G. Finlayson, Corey Chivers, Irene Chen, Matthew McDermott, Jaz Kandola, Adrian V. Dalca, Andrew Beam, Madalina Fiterau, Tristan Naumann
Journal: JAMA Network Open (2019)

<h3>Importance</h3> The use of machine learning applications related to health is rapidly increasing and may have the potential to profoundly affect the field of health care. <h3>Objective</h3> To analyze submissions to a popular machine learning for health venue to assess the current state of research, including areas of methodologic and clinical focus, limitations, and underexplored areas. <h3>Design, Setting, and Participants</h3> In this data-driven qualitative analysis, 166 accepted manuscript submissions to the Third Annual Machine Learning for Health workshop at the 32nd Conference on Neural Information Processing Systems on December 8, 2018, were analyzed to understand research focus, progress, and trends. Experts reviewed each submission against a rubric to identify key data points, statistical modeling and analysis of submitting authors was performed, and research topics were quantitatively modeled. Finally, an iterative discussion of topics common in submissions and invited speakers at the workshop was held to identify key trends. <h3>Main Outcomes and Measures</h3> Frequency and statistical measures of methods, topics, goals, and author attributes were derived from an expert review of submissions guided by a rubric. <h3>Results</h3> Of the 166 accepted submissions, 58 (34.9%) had clinician involvement and 83 submissions (50.0%) that focused on clinical practice included clinical collaborators. A total of 97 data sets (58.4%) used in submissions were publicly available or required a standard registration process. Clinical practice was the most common application area (70 manuscripts [42.2%]), with brain and mental health (25 [15.1%]), oncology (21 [12.7%]), and cardiovascular (19 [11.4%]) being the most common specialties. <h3>Conclusions and Relevance</h3> Trends in machine learning for health research indicate the importance of well-annotated, easily accessed data and the benefit from greater clinician involvement in the development of translational applications.
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Authors: Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars, James L. Gulley
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti–PD-L1) monotherapy in patients with mRCC as either first-line (1 L) or second-line (2 L) treatment. <h3>Methods</h3> Patients with mRCC with a clear-cell component who were treatment naive (1 L subgroup) or had disease progression after one prior line of therapy (2 L subgroup) received avelumab 10 mg/kg intravenous infusion every 2 weeks. Endpoints included confirmed best overall response, duration of response (DOR), progression-free survival (PFS), overall survival (OS), PD-L1 expression, and safety. <h3>Results</h3> A total of 62 patients were enrolled in the 1 L subgroup, and 20 patients were enrolled in the 2 L subgroup. In the 1 L and 2 L subgroups, confirmed objective response rates were 16.1 and 10.0%, median DOR was 9.9 months (95% confidence interval [CI], 2.8–not evaluable) and not evaluable (95% CI, 6.9–not evaluable), median PFS was 8.3 months (95% CI, 5.5–9.5) and 5.6 months (95% CI, 2.3–9.6), and median OS was not evaluable (95% CI, not evaluable) and 16.9 months (95% CI, 8.3–not evaluable), respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 51 patients in the 1 L subgroup (82.3%) and 14 patients in the 2 L subgroup (70.0%). Grade ≥ 3 TRAEs occurred in eight patients in the 1 L subgroup (12.9%) and one patient in the 2 L subgroup (5.0%). No treatment-related deaths occurred. <h3>Conclusion</h3> Avelumab showed clinical activity and a manageable safety profile in both the 1 L and 2 L treatment setting in patients with mRCC. These data support the use of avelumab in combination with other agents in mRCC. <h3>Trial registration</h3> ClinicalTrials.gov: NCT01772004; registered 21 January, 2013.
Prediction of Sex-Specific Suicide Risk Using Machine Learning and Single-Payer Health Care Registry Data From Denmark
Authors: Jaimie L. Gradus, Anthony J. Rosellini, Erzsébet Horváth-Puhó, Amy E. Street, Isaac Galatzer-Levy, Tammy Jiang, Timothy L. Lash, Henrik T. Sørensen
Journal: JAMA Psychiatry (2019)

Suicide is a public health problem, with multiple causes that are poorly understood. The increased focus on combining health care data with machine-learning approaches in psychiatry may help advance the understanding of suicide risk.To examine sex-specific risk profiles for death from suicide using machine-learning methods and data from the population of Denmark.A case-cohort study nested within 8 national Danish health and social registries was conducted from January 1, 1995, through December 31, 2015. The source population was all persons born or residing in Denmark as of January 1, 1995. Data were analyzed from November 5, 2018, through May 13, 2019.Exposures included 1339 variables spanning domains of suicide risk factors.Death from suicide from the Danish cause of death registry.A total of 14 103 individuals died by suicide between 1995 and 2015 (10 152 men [72.0%]; mean [SD] age, 43.5 [18.8] years and 3951 women [28.0%]; age, 47.6 [18.8] years). The comparison subcohort was a 5% random sample (n = 265 183) of living individuals in Denmark on January 1, 1995 (130 591 men [49.2%]; age, 37.4 [21.8] years and 134 592 women [50.8%]; age, 39.9 [23.4] years). With use of classification trees and random forests, sex-specific differences were noted in risk for suicide, with physical health more important to men's suicide risk than women's suicide risk. Psychiatric disorders and possibly associated medications were important to suicide risk, with specific results that may increase clarity in the literature. Generally, diagnoses and medications measured 48 months before suicide were more important indicators of suicide risk than when measured 6 months earlier. Individuals in the top 5% of predicted suicide risk appeared to account for 32.0% of all suicide cases in men and 53.4% of all cases in women.Despite decades of research on suicide risk factors, understanding of suicide remains poor. In this study, the first to date to develop risk profiles for suicide based on data from a full population, apparent consistency with what is known about suicide risk was noted, as well as potentially important, understudied risk factors with evidence of unique suicide risk profiles among specific subpopulations.
P1.01-43 Programmed-Death Ligand 1 Spectrum in a Large Cohort of Genetically Characterized Non-Small Cell Lung Cancer Patients
Authors: E. Marin, C. Teixido, E. Carmona, A. Arcocha, C. Cabrera, D. Martinez, P. Jares, N. Viñolas, A. Prat, N. Reguart
Journal: Journal of Thoracic Oncology (2019)
P2.03-04 The Prognostic Value of Serological Tumor Markers in Lung Cancer – Analysis of 13,373 Cases
Authors: T. Muley, K. Senghas, S. Kobinger, M. Meister, M. Schneider, E. Herpel, M. Thomas, H. Winter, C. Heussel, F. Herth
Journal: Journal of Thoracic Oncology (2019)
P2.01-37 Lower Risk of Hypercoagulability in Non-Small Cell Lung Cancer Patients with EGFR Mutations
Authors: S. Ohara, K. Suda, T. Takemoto, M. Nishino, M. Chiba, T. Fujino, A. Hamada, T. Koga, J. Soh, T. Misudomi
Journal: Journal of Thoracic Oncology (2019)
MA19.09 Assessing Clinical Frailty in Advanced Lung Cancer Patients - An Opportunity to Improve Patient Outcomes?
Authors: F. Gomes, K. Baker, J. Woods, J. Bruce, M. Eaton, P. Higham, L. Cove-Smith, A. Garbett, A. Cree, C. Ng, F. Blackhall, N. Bayman
Journal: Journal of Thoracic Oncology (2019)
Concordance for clonal hematopoiesis is limited in elderly twins
Authors: Margarete A. Fabre, Thomas McKerrell, Maximillian Zwiebel, M. S. Vijayabaskar, Naomi Park, Philippa M. Wells, Roland Rad, Panagiotis Deloukas, Kerrin Small, Claire J. Steves, George S. Vassiliou
Journal: Blood (2019)
P2.06-21 Efficacy and Safety of Tumor Treating Fields Delivery to the Thorax by Computational Simulations
Authors: N. Urman, Z. Bomzon, H. Hershkovich, O. Yesharim, A. Naveh, U. Weinberg, E. Kirson, Y. Palti
Journal: Journal of Thoracic Oncology (2019)
OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer
Authors: M. Reck, D. Rodríguez-Abreu, A.G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, S. Rao, K. Hotta, T. Garay, E. Jensen, V. Ebiana, J.R. Brahmer
Journal: Journal of Thoracic Oncology (2019)
OA03.02 Effect of Anlotinib in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial
Authors: Q. Wang, Y. Cheng, K. Li, J. Shi, B. Han, L. Wu, G. Chen, J. He, J. Wang, H. Qin, X. Li
Journal: Journal of Thoracic Oncology (2019)
EP1.04-33 Pembrolizumab with High PD-L1: Who Are Non-Responders?
Authors: F. Shigematsu, Y. Kogure, A. Torii, A. Yamada, A. Ishida, H. Niwa, M. Nakahata, S. Oka, C. Kitagawa, M. Oki, H. Saka
Journal: Journal of Thoracic Oncology (2019)
EP1.03-16 Lysimachia Capillipes Capilliposide C Restores Radiation Sensitivity in Radiation Resistant Lung Cancer Cells by Enhancing ERRFI1 Expression
Authors: K. Wu, B. Wang, Y. Xu, J. Feng, L. Zhu, X. Chen, B. Xia, S. Zhang, X. Chen, S. Ma
Journal: Journal of Thoracic Oncology (2019)
Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats
Authors: Ian K. Styles, Orlagh M. Feeney, Tri-Hung Nguyen, Daniel H.S. Brundel, David W. Kang, Renee Clift, Michelle P. McIntosh, Christopher J.H. Porter
Journal: Journal of Controlled Release (2019)
Functionalized helical fibre bundles of carbon nanotubes as electrochemical sensors for long-term in vivo monitoring of multiple disease biomarkers
Authors: Liyuan Wang, Songlin Xie, Zhiyuan Wang, Fei Liu, Yifan Yang, Chengqiang Tang, Xiaoying Wu, Peng Liu, Yongjing Li, Hexige Saiyin, Shuang Zheng, Xuemei Sun, Fan Xu, Hongbo Yu, Huisheng Peng
Journal: Nature Biomedical Engineering (2019)
P2.17-23 The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study
Authors: Y. Eralp, N. Ak, D. Yilmazbayhan, B. Özkan, F. Ferhatoğlu, A. Demirkazik, S. Dizbay Sak, Ş. Dilege, S. Tanju, A. Toker, P. Bulutay, P. Firat, N. Molinas Mandel, S. Kilickap, S. Onder, E. Dikmen, O. Alan, P.F. Yumuk, E. Bozkurtlar, T. Lacin, A. Ozturk, C. Kocaturk, K. Karapinar, N. Urer, B. Oyan Uluc
Journal: Journal of Thoracic Oncology (2019)
MA13.09 Cisplatin Sustains Lung Cancer Metastasis Through the Systemic Activation of SDF-1/CXCR4 Axis
Authors: G. Bertolini, V. Cancila, C. Tripodo, G. Sozzi, G. Lo Russo, O. Fortunato, M. Milione, G. Centonze, M. Tortoreto, S. Scala, L. Roz
Journal: Journal of Thoracic Oncology (2019)
P1.04-40 Serum Perforin Levels During the First Cycle of Anti-PD-1 Antibody Therapies in Non-Small Cell Lung Cancer
Authors: T. Ota, T. Fukui, Y. Nakahara, T. Takeda, J. Uchino, T. Mouri, K. Kudo, S. Nakajima, T. Suzumura, T. Okabe, H. Hayashi, N. Miyatake, Y. Nakano, M. Terashima, Y. Hasegawa, H. Tsukuda, K. Matsui, N. Masuda, M. Fukuoka
Journal: Journal of Thoracic Oncology (2019)
MA12.03 PARP Inhibitor Sensitivity Does Not Depend on BAP1 but Is Enhanced by Temozolomide in MGMT Deficient Human Mesothelioma Cells
Authors: D. Rathkey, M. Khanal, J. Murai, J. Zhang, Q. Jiang, B. Morrow, C. Evans, R. Chari, M. Sengupta, A. Thomas, Y. Pommier, R. Hassan
Journal: Journal of Thoracic Oncology (2019)
P1.01-58 Comprehensive Serial Biomaterial Acquisition in Advanced NSCLC: Feasibility, Challenges and Perspectives
Authors: S. Wessels, P. Christopoulos, T. Muley, M. Meister, I. Heinzmann-Groth, A. Warth, E. Herpel, A. Stenzinger, S. Hummler, U. Klingmueller, J. Kuon, C. Heussel, R. Eberhardt, F. Herth, H. Winter, H. Bischoff, M. Reck, R. Huber, M. Thomas, M. Schneider
Journal: Journal of Thoracic Oncology (2019)
P1.14-49 The Role of ctDNA Detection (Liquid Biopsy) in Patients with NSСLC
Authors: A. Zhabina, F. Moiseenko, M. Stepanova, V. Moissenko, A. Mjslik, N. Volkov, D. Krylova, N. Rysev
Journal: Journal of Thoracic Oncology (2019)
Whole exome sequencing identified ATP6V1C2 as a novel candidate gene for recessive distal renal tubular acidosis
Authors: Tilman Jobst-Schwan, Verena Klämbt, Maureen Tarsio, John F. Heneghan, Amar J. Majmundar, Shirlee Shril, Florian Buerger, Isabel Ottlewski, Boris E. Shmukler, Rezan Topaloglu, Seema Hashmi, Farkhanda Hafeez, Francesco Emma, Marcella Greco, Guido F. Laube, Hanan M. Fathy, Martin Pohl, Jutta Gellermann, Danko Milosevic, Michelle A. Baum, Shrikant Mane, Richard P. Lifton, Patricia M. Kane, Seth L. Alper, Friedhelm Hildebrandt
Journal: Kidney International (2019)
P1.11-14 SGLT2 Is a Diagnostic and Therapeutic Target for Early-Stage Lung Adenocarcinoma
Authors: B. Villegas, E. Koziolek, J. Liu, J. Barrio, W.D. Wallace, D. Elashoff, D. Aberle, J. Yanagawa, D. Shackelford, S. Dubinett, C. Scafoglio
Journal: Journal of Thoracic Oncology (2019)
EP1.06-09 Mesothelial Tumors Registry in Spain: A Retrospective Multicenter Study
Authors: P. Cruz, S. Martínez Recio, X. Mielgo, V. Sotelo Peña, L.E. Chara, I. Nalda Ariza, E. Martinez Moreno, Y. Lage Alfranca, A. Velastegui, L. Gutiérrez Sainz, J. De Castro Carpeno
Journal: Journal of Thoracic Oncology (2019)
Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in HemophiliaA Dogs
Authors: Tongyao Liu, David Lillicrap, Xin Zhang, Andrea Labelle, Sandra Powell, Baisong Mei, John E. Murphy, Glenn F. Pierce, Haiyan Jiang
Journal: Blood (2008)
P1.13-01 The Importance of Staging of Lung Cancers, 30 mm or Less, Separately for Subsolid and Solid Nodules
Authors: Y. Wang, R. Yip, Y. Zhu, E. Fevrier, T. Ma, M. Van Gerwen, D. Yankelevitz, R. Flores, C. Henschke
Journal: Journal of Thoracic Oncology (2019)